Connection

Ioana Agache to Humans

Back to Details
This is a "connection" page, showing publications Ioana Agache has written about Humans.
Ioana Agache
Connection Strength
0.149
Humans
  1. Real-life impact of COVID-19 pandemic lockdown on the management of pediatric and adult asthma: A survey by the EAACI Asthma Section. Allergy. 2021 09; 76(9):2776-2784.
    View in: PubMed
    Score: 0.008
  2. COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy. 2021 03; 76(3):648-676.
    View in: PubMed
    Score: 0.007
  3. ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy. 2021 03; 76(3):689-697.
    View in: PubMed
    Score: 0.007
  4. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Invest. 2019 03 11; 129(4):1493-1503.
    View in: PubMed
    Score: 0.007
  5. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy. 2019 03; 74(3):449-463.
    View in: PubMed
    Score: 0.006
  6. Highlights and recent developments in food and drug allergy, and anaphylaxis in EAACI Journals (2017). Pediatr Allergy Immunol. 2018 12; 29(8):801-807.
    View in: PubMed
    Score: 0.006
  7. Endotypes in allergic diseases. Curr Opin Allergy Clin Immunol. 2018 06; 18(3):177-183.
    View in: PubMed
    Score: 0.006
  8. EAACI guidelines on allergen immunotherapy-Out with the old and in with the new. Allergy. 2018 04; 73(4):737-738.
    View in: PubMed
    Score: 0.006
  9. Food allergy in EAACI journals (2016). Pediatr Allergy Immunol. 2017 Dec; 28(8):825-830.
    View in: PubMed
    Score: 0.006
  10. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018 01; 141(1):442-445.
    View in: PubMed
    Score: 0.006
  11. COVID-19 vaccines-The way forward. Allergy. 2022 01; 77(1):15-16.
    View in: PubMed
    Score: 0.002
  12. Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021 10; 76(10):2952-2964.
    View in: PubMed
    Score: 0.002
  13. COVID-19 pandemic and allergen immunotherapy-an EAACI survey. Allergy. 2021 11; 76(11):3504-3516.
    View in: PubMed
    Score: 0.002
  14. One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2. Allergy. 2022 01; 77(1):55-71.
    View in: PubMed
    Score: 0.002
  15. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy. 2021 06; 76(6):1640-1660.
    View in: PubMed
    Score: 0.002
  16. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines - An EAACI-ARIA Position Paper. Allergy. 2021 06; 76(6):1624-1628.
    View in: PubMed
    Score: 0.002
  17. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. 2021 06; 76(6):1629-1639.
    View in: PubMed
    Score: 0.002
  18. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA2 LEN consensus. Allergy. 2021 08; 76(8):2354-2366.
    View in: PubMed
    Score: 0.002
  19. Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort. Allergy. 2021 06; 76(6):1765-1775.
    View in: PubMed
    Score: 0.002
  20. Management of patients with chronic rhinosinusitis during the COVID-19 pandemic-An EAACI position paper. Allergy. 2021 03; 76(3):677-688.
    View in: PubMed
    Score: 0.002
  21. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. Int Arch Allergy Immunol. 2021; 182(4):324-338.
    View in: PubMed
    Score: 0.002
  22. Spices to Control COVID-19 Symptoms: Yes, but Not Only…. Int Arch Allergy Immunol. 2021; 182(6):489-495.
    View in: PubMed
    Score: 0.002
  23. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement. Allergy. 2020 11; 75(11):2764-2774.
    View in: PubMed
    Score: 0.002
  24. Advances and recent developments in asthma in 2020. Allergy. 2020 12; 75(12):3124-3146.
    View in: PubMed
    Score: 0.002
  25. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy. 2020 10; 75(10):2440-2444.
    View in: PubMed
    Score: 0.002
  26. Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives-A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020 10; 75(10):2445-2476.
    View in: PubMed
    Score: 0.002
  27. A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy. 2020 10; 75(10):2503-2541.
    View in: PubMed
    Score: 0.002
  28. Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement. Allergy. 2020 07; 75(7):1546-1554.
    View in: PubMed
    Score: 0.002
  29. Impact of COVID-19 on Pediatric Asthma: Practice Adjustments and Disease Burden. J Allergy Clin Immunol Pract. 2020 09; 8(8):2592-2599.e3.
    View in: PubMed
    Score: 0.002
  30. ARIA masterclass 2018: From guidelines to real-life implementation. Rhinology. 2019 Oct 01; 57(5):392-399.
    View in: PubMed
    Score: 0.002
  31. Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019. Allergy. 2020 04; 75(4):936-940.
    View in: PubMed
    Score: 0.002
  32. Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases-11. J Allergy Clin Immunol. 2019 09; 144(3):627-633.
    View in: PubMed
    Score: 0.002
  33. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol. 2019 07; 144(1):135-143.e6.
    View in: PubMed
    Score: 0.002
  34. Much ado about Biologicals: Highlights of the Master Class on Biologicals, Prague, 2018. Allergy. 2019 04; 74(4):837-840.
    View in: PubMed
    Score: 0.002
  35. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate. J Allergy Clin Immunol. 2019 04; 143(4):1395-1402.
    View in: PubMed
    Score: 0.002
  36. mySinusitisCoach: patient empowerment in chronic rhinosinusitis using mobile technology. Rhinology. 2018 Sep 01; 56(3):209-215.
    View in: PubMed
    Score: 0.002
  37. Electronic Clinical Decision Support System for allergic rhinitis management: MASK e-CDSS. Clin Exp Allergy. 2018 12; 48(12):1640-1653.
    View in: PubMed
    Score: 0.002
  38. The urgent need for a harmonized severity scoring system for acute allergic reactions. Allergy. 2018 09; 73(9):1792-1800.
    View in: PubMed
    Score: 0.002
  39. Differences in Reporting the Ragweed Pollen Season Using Google Trends across 15 Countries. Int Arch Allergy Immunol. 2018; 176(3-4):181-188.
    View in: PubMed
    Score: 0.002
  40. Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the MASK study. Allergy. 2018 08; 73(8):1622-1631.
    View in: PubMed
    Score: 0.002
  41. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy. 2018 04; 73(4):739-743.
    View in: PubMed
    Score: 0.002
  42. EAACI Position paper on the standardization of nasal allergen challenges. Allergy. 2018 08; 73(8):1597-1608.
    View in: PubMed
    Score: 0.002
  43. Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: An analysis from the EAACI AIT Guidelines Project. Allergy. 2018 04; 73(4):816-826.
    View in: PubMed
    Score: 0.002
  44. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018 04; 73(4):827-836.
    View in: PubMed
    Score: 0.001
  45. EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. Allergy. 2018 04; 73(4):744-764.
    View in: PubMed
    Score: 0.001
  46. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018 04; 73(4):799-815.
    View in: PubMed
    Score: 0.001
  47. EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. Allergy. 2018 04; 73(4):765-798.
    View in: PubMed
    Score: 0.001
  48. EAACI guidelines on allergen immunotherapy: Prevention of allergy. Pediatr Allergy Immunol. 2017 Dec; 28(8):728-745.
    View in: PubMed
    Score: 0.001
  49. National clinical practice guidelines for allergen immunotherapy: An international assessment applying AGREE-II. Allergy. 2018 03; 73(3):664-672.
    View in: PubMed
    Score: 0.001
  50. Impact of Rhinitis on Work Productivity: A Systematic Review. J Allergy Clin Immunol Pract. 2018 Jul - Aug; 6(4):1274-1286.e9.
    View in: PubMed
    Score: 0.001
  51. EUFOREA Rhinology Research Forum 2016: report of the brainstorming sessions on needs and priorities in rhinitis and rhinosinusitis. Rhinology. 2017 Sep 01; 55(3):202-210.
    View in: PubMed
    Score: 0.001
  52. Challenges in the implementation of EAACI guidelines on allergen immunotherapy: A global perspective on the regulation of allergen products. Allergy. 2018 Jan; 73(1):64-76.
    View in: PubMed
    Score: 0.001
  53. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - EIP on AHA Twinning Reference Site (GARD research demonstration project). Allergy. 2018 Jan; 73(1):77-92.
    View in: PubMed
    Score: 0.001
  54. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017 Dec; 72(12):1825-1848.
    View in: PubMed
    Score: 0.001
  55. [ARIA 2016 executive summary: Integrated care pathways for predictive medicine throughout the life cycle in Argentina]. Rev Alerg Mex. 2017 Jul-Sep; 64(3):298-308.
    View in: PubMed
    Score: 0.001
  56. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017 Oct; 140(4):950-958.
    View in: PubMed
    Score: 0.001
  57. Non-allergic rhinitis: Position paper of the European Academy of Allergy and Clinical Immunology. Allergy. 2017 Nov; 72(11):1657-1665.
    View in: PubMed
    Score: 0.001
  58. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017 Sep; 72(9):1297-1305.
    View in: PubMed
    Score: 0.001
  59. Google Trends terms reporting rhinitis and related topics differ in European countries. Allergy. 2017 Aug; 72(8):1261-1266.
    View in: PubMed
    Score: 0.001
  60. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb; 137(2):358-68.
    View in: PubMed
    Score: 0.001
  61. Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. Allergy. 2011 Apr; 66(4):458-68.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.